Xofigo IV injection, manufactured by Bayer Pharmaceutical, contains Radium chloride (223Ra). This alpha particle-emitting radioactive therapeutic agent is used to treat castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease. This 1 dose vial has a YJ code of 4291432A1025.
Xofigo IV injection
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).